Welcome to Modal Window plugin
Noncontact Low-Frequency Ultrasound Therapy
UltraMIST® is a low-frequency ultrasound system that delivers ultrasound to the treatment site using a noncontact fluid such as saline. UltraMIST® is the next generation of MIST Therapy® and maintains the same mechanism of action as the MIST Therapy used in published clinical studies.
Clinical Overview
A retrospective analysis evaluated the effects of noncontact low-frequency ultrasound (NLFU) on the healing of suspected deep tissue injuries (SDTIs). Wound progression was assessed before and after treatment using three clinical characteristics: wound surface area, wound color and tissue assessment, and skin integrity.
If left unresolved, SDTIs may progress into full-thickness Stage 3 or Stage 4 pressure ulcers. Altering this progression is clinically important, as current standard of care alone results in favorable outcomes–defined as spontaneous resolution or progression to Stage 2 pressure ulcers–in only 22% of SDTIs.
This retrospective study included 85 patients with a total of 127 suspected deep tissue injuries. Both groups received standard of care, which included repositioning schedules with assistive repositioning or turning devices, off-loading boots, and dietetic consultation.
A retrospective analysis evaluated the effects of noncontact low-frequency ultrasound (NLFU) on the healing of suspected deep tissue injuries (SDTIs). Wound progression was assessed before and after treatment using three clinical characteristics: wound surface area, wound color and tissue assessment, and skin integrity.
If left unresolved, SDTIs may progress into full-thickness Stage 3 or Stage 4 pressure ulcers. Altering this progression is clinically important, as current standard of care alone results in favorable outcomes–defined as spontaneous resolution or progression to Stage 2 pressure ulcers–in only 22% of SDTIs.
To evaluate healing progression, a severity scale ranging from 3 to 18 was developed, with higher scores indicating greater wound severity. Patients treated with MIST Therapy® in addition to standard of care demonstrated a reduction in wound severity, while patients receiving standard of care alone showed an increase in severity.
Severity score change observed in the study:
MIST Therapy® + standard of care: –1.45
Standard of care control group: +1.06
Final pressure ulcer staging at discharge demonstrated that substantially more suspected deep tissue injuries resolved spontaneously or improved to Stage 2 pressure ulcers with the addition of MIST Therapy®.
The treatment group also demonstrated a reduction in unstageable wounds. At discharge, 9% of wounds in the MIST Therapy® group were classified as unstageable, compared to 40% in the standard-of-care control group.
Explore UltaMIST® resources for a deeper look into our wound care product solutions. Download the materials below to learn more.
We are excited to embark on this journey and we invite wound care professionals and providers alike to join us. Together, we can make a difference in the lives of patients and create a brighter future. Contact us today to learn more about how Total Ancillary can help.
Welcome to Modal Window plugin